Circulating tumor cells (CTCs) are an early warning sign of cancer
Tumors begin to grow up as many as 5 to 10 years before they are detected. Circulating Tumor Cells (CTCs) enter the bloodstream from the earliest days of tumor development. Rarcells’ proprietary ISET® (Isolation by Size of Tumor cells) device is a highly accurate, non-invasive liquid biopsy technology, designed to detect cancer earlier and prevent metastases.
Our technology is designed to detect cancer earlier
Many liquid biopsy tests are based on circulating tumor DNA (ctDNA). ctDNA is easier to isolate than CTCs, but has been consistently reported to have have low sensitivity at early stages of cancer.
The latest version of Rarecells’ ISET® technology allows CTC-DNA to be obtained with the highest sensitivity, providing high quality, enriched tumor CTC-DNA for accurate liquid biopsy tests. Furthermore, the new ISET® process optimizes the extraction of CTC-DNA and ctDNA from the same blood sample. The combined analysis of both CTC-DNA and ctDNA is expected to overcome the low sensitivity of ctDNA in early-stage cancer settings and provide a more accurate solution for detection of early stage cancer and cancer recurrence.
Rarecells’ device is a certified CE-Mark In Vitro Diagnostic (CE-IVD) platform with the demonstrated and CE-Mark validated unparalleled ability to extract down to a single cancer cell from among 50 billion blood cells in a 10 ml blood sample.
A strong base of published evidence
ISET®’s groundbreaking sensitivity and specificity have been established through 110+ high-level, peer-reviewed and independent scientific publications. Studies demonstrated the efficacy and utility of tests using ISET®-collected cells in early detection of cancer, cancer prognosis, and non-invasive theranostics.
0
TYPES OF CANCER
0
+
CLINICAL STUDIES
0
K+
PATIENTS STUDIED